Nineteen health organisations and doctors' groups have written to Andy Burnham urging him to scrap the UK-US medicines trade deal, in a letter coordinated by the SOS NHS coalition and published exclusively by The Guardian on July 7. Signatories include Medact, the Doctors' Association UK and Doctors in Unite. The letter lands as Burnham, the MP for Makerfield, is expected to succeed Keir Starmer as Labour leader and prime minister within weeks — timing that gives the demand more immediate political weight than a routine campaign missive.

The deal in question was announced by the UK government on 1 December 2025 as part of the broader UK-US Economic Prosperity Deal, with full legal text agreed by 2 April 2026 Reuters. Its headline commercial feature is straightforward: zero tariffs on UK pharmaceutical exports to the US for three years, a provision the Association of the British Pharmaceutical Industry welcomed as a boost to UK life sciences competitiveness ABPI. The mechanism that has drawn sustained criticism is on the pricing side. Under the agreement, NICE's cost-effectiveness threshold — the ceiling per quality-adjusted life year (QALY) that determines whether the NHS will fund a new drug — rose from £20,000–£30,000 to £25,000–£35,000, an increase of 17% to 25% Inside EU Life Sciences. That threshold shift raises the price NICE will tolerate for new medicines, which critics argue effectively imports elements of US drug pricing into a system built around single-payer cost control.

Compounding that concern is the statutory rebate scheme. In 2025, before the deal, pharmaceutical companies selling to the NHS faced a rebate rate of 23% under the UK's statutory pricing mechanism EurekAlert. Analysis cited in the SOS NHS letter estimates that £44.7bn in NHS cash will be diverted from health services by 2036 to cover the cost of new medicines under the deal, unless the Treasury provides additional funding to offset it. Academics from the University of York, the University of Liverpool and Christchurch hospital in New Zealand have translated that diversion into mortality terms, projecting 229,000 excess deaths by 2036 if NHS spending is squeezed as modelled. The Guardian first reported this figure on July 1 and followed with a video explainer in its "The Latest" series on July 2 The Guardian. The estimate has since become the organising statistic around which the SOS NHS coalition's campaign is built.

Legal challenge has been building in parallel with the political lobbying. The New Statesman reported in May that campaigners were preparing legal action against the government over the deal, framing it in stark terms as a threat to the foundational principles of NHS provision New Statesman. Dr Tony O'Sullivan, co-chair of Keep Our NHS Public and a retired consultant paediatrician, and Hope Worsdale of the patient campaign group Just Treatment are among those who have put their names to the current letter, giving it both clinical and patient-advocacy standing rather than a purely activist signature.

Beyond drug pricing, the letter widens its target list considerably. Signatories also want Burnham to revisit PFI arrangements underpinning new neighbourhood health centres, reverse recent NHS job cuts, halt the expansion of private providers across NHS-commissioned services, and reconsider Palantir's NHS data contract. Bundling these demands together signals that SOS NHS is treating the drug deal less as an isolated trade dispute and more as one thread in a wider argument about creeping marketisation and outsourcing within the health service — an argument that predates this specific agreement but has found a sharper focus in it.

The politics here are worth sitting with. Burnham built much of his political identity on NHS advocacy going back to his time as health secretary, and campaigners are betting that a leadership transition creates a rare window to reopen an agreement that Starmer's government has already signed and defended. Whether an incoming prime minister would unwind a bilateral trade commitment with the US — one bound up in a broader Economic Prosperity Deal — is a different question from whether he sympathises with the underlying critique. Renegotiating or scrapping the pharmaceutical annex alone, without touching the tariff provisions the industry values, would require threading a needle that has not been publicly attempted by any UK government to date.

The Commons Library's own briefing situates the pharmaceutical agreement squarely within that larger Economic Prosperity Deal architecture, a framing that matters for anyone assessing how easily one component could be excised without reopening the whole package Commons Library. That structural entanglement — trade tariffs bundled with pricing thresholds — is likely to be the real terrain on which any future renegotiation is fought, regardless of who occupies Downing Street when the argument resumes.